AprilBio KRX:397030KOSDAQ
에이프릴바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked21since Sep 11
In Q2 2026, AprilBio reported an operating loss of ₩2.9bn. AprilBio (에이프릴바이오) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 22 with 1 article. The most common catalyst was tech & capacity (1). It was most often mentioned alongside Oncocross.
Filing signals Control change 4 quarters of losses Screener
AprilBio quarterly results separate, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | −₩2.9bn | −₩2.0bn |
| Q1 2026 | −₩2.2bn | ₩201m |
| Q4 2025 derived | −₩2.0bn | −₩2.3bn |
| Q3 2025 | −₩2.5bn | −₩5.0bn |
| Q2 2025 | −₩2.7bn | −₩3.1bn |
| Q1 2025 | −₩110m | ₩594m |
| Q4 2024 derived | ₩3.7bn | ₩6.6bn |
| Q3 2024 | −₩2.4bn | −₩3.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
AprilBio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest AprilBio news Korean headlines
-
‘APB-R3’ 2회 투여로 12주 효과…에이프릴바이오 ‘SAFA’ 반전 단초
1 more on this story · 1 outlets
- ‘APB-R3’ 2회 투여로 12주 효과…에이프릴바이오 ‘SAFA’ 반전 단초이데일리 · Oct 2 06:01
-
에이프릴바이오, 글로벌 빅파마 출신 황선진 부사장 영입…파트너링 박차
5 more on this story · 4 outlets
- 에이프릴바이오, 황선진 부사장 영입…글로벌 파트너링 추진머니투데이 · Sep 29 09:25
- 에이프릴바이오, 빅파마 출신 황선진 부사장 영입…BD 역량 강화이데일리 · Sep 29 09:27
- 에이프릴바이오, 빅파마 출신 황선진 부사장 영입…BD 역량 강화이데일리 · Sep 29 09:28
- 에이프릴바이오, 글로벌 제약사 출신 황선진 부사장 영입…해외 파트너링 강화이뉴스투데이 · Sep 29 10:06
- 에이프릴바이오, 암젠 출신 황선진 부사장 영입조선비즈 · Sep 29 19:04